Clinical Trial

Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this clinical study is to look at the safety of the medicine Cagrilintide when compared to placebo in people who do not tolerate marketed glucagon-like peptide-1 (GLP-1) therapies and who live with overweight or obesity. Participants will get either Cagrilintide (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participant will get is decided by chance. The study will last for about 8 months.
Protocol Amendment History 1 change
critical Recruitment opened 2026-06-26
Trial Details
NCT Number NCT07607587
Lead Sponsor Novo Nordisk A/S
Conditions Obesity, Overweight
Enrollment 114 participants
Start Date 2026-05-29
Primary Completion 2027-11-19 (estimated)
Study Completion 2027-11-19 (estimated)
Updated on ClinicalTrials.gov 2026-06-25